LISATA THERAPEUTICS INC (LSTA) Stock News

USA - Nasdaq - NASDAQ:LSTA - US1280583022 - Common Stock

2 USD

-0.04 (-1.96%)

Last: 12/12/2025, 8:00:00 PM

2.0881 USD

+0.09 (+4.4%)

After Hours: 12/12/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LSTA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

a month ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

2 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

2 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

2 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

3 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

3 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

3 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

5 months ago - By: Yahoo Finance

Lisata Secures New Composition of Matter Patent for Certepetide

5 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

5 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

5 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

5 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

6 months ago - By: Lisata Therapeutics, Inc.

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

6 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

6 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

6 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the 2025 BIO International Convention

6 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the 2025 BIO International Convention

7 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

8 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

8 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Research License with Catalent

9 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the Investival Showcase USA

9 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the Investival Showcase USA

9 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

9 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

10 months ago - By: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update